Immunic (IMUX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Immunic (IMUX) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.33 of bullish evidence against -0.38 bearish.

Immunic last closed at $7.96, -7.87% on the session.

Against the IVW growth benchmark the position is -8.84% over the forecast window.

The read is built from 15 underlying insights — 1 bullish and 14 bearish.

Agreement across those insights is 93%.

35 graded predictions for IMUX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Immunic in the 7th percentile on return on equity, where 100 is best.

Immunic is classified under Health Care / Biotechnology, with a market capitalisation of $117.88M.

StockMap tracks Immunic as the 193rd largest of the 250 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 124 Neutral, 117 Moderate Underperform, 8 Strong Underperform and 1 Moderate Outperform.

On that composite Immunic ranks 215th of 250 in the group, against a group median of -0.21.